keyword
MENU ▼
Read by QxMD icon Read
search

oncology lymphoma

keyword
https://www.readbyqxmd.com/read/28802171/parental-occupational-exposure-to-benzene-and-the-risk-of-childhood-cancer-a-census-based-cohort-study
#1
Ben Daniel Spycher, Judith Eva Lupatsch, Anke Huss, Johannes Rischewski, Christina Schindera, Adrian Spoerri, Roel Vermeulen, Claudia Elisabeth Kuehni
BACKGROUND: Previous studies on occupational exposures in parents and cancer risks in their children support a link between solvents and paints with childhood leukaemia. Few studies have focused specifically on benzene. OBJECTIVES: To examine whether parental occupational exposure to benzene is associated with an increased cancer risk in a census-based cohort of children. METHODS: From a census-based cohort study in Switzerland, we included children aged <16years at national censuses (1990, 2000)...
August 9, 2017: Environment International
https://www.readbyqxmd.com/read/28802087/variant-histology-igd-and-cd30-expression-in-low-risk-pediatric-nodular-lymphocyte-predominant-hodgkin-lymphoma-a-report-from-the-children-s-oncology-group
#2
Ramona Vesna Untanu, Jason Back, Burton Appel, Qinglin Pei, Lu Chen, Allen Buxton, David C Hodgson, Peter F Ehrlich, Louis S Constine, Cindy L Schwartz, Robert E Hutchison
BACKGROUND: Histologic prognostic factors have been described for nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). This study examines histologic and immunophenotypic variants in a clinical trial for pediatric NLPHL. PROCEDURE: One hundred sixty-eight cases of localized NLPHL were examined for histologic variants, CD30 and immunoglobulin D (IgD) expression, and outcome. Histologic types were scored categorically as 0 = 0, 1 ≤ 25%, and 2 > 25% of the sample...
August 12, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28799485/monoclonal-antibodies-a-review
#3
Surjit Singh, Nitish Kumar, Pradeep Dwiwedi, Jaykaran Charan, Rimplejeet Kaur, Preeti Sidhu, Vinay Kumar Chugh
Over the last three decades, monoclonal antibodies (MAbs) have made a striking transformation from scientific tools to powerful human therapeutics. Muromonab CD3 a murine MAb, was first FDA approved therapeutic MAb for prevention of kidney transplant rejection. Since its approval in 1986, there has been decline in the further application and approvals until the late 1990s when the first chimeric Mab, Rituximab was approved for the treatment of low grade B cell lymphoma in 1997. With the approval by licensing authorities of chimeric, followed by humanized and then fully human monoclonal antibodies, rate of approval and monoclonal antibodies available in the market for the treatment of various diseases has increased dramatically...
August 9, 2017: Current Clinical Pharmacology
https://www.readbyqxmd.com/read/28792782/emerging-antibody-drug-conjugates-for-treating-lymphoid-malignancies
#4
Anna Wolska-Washer, Pawel Robak, Piotr Smolewski, Tadeusz Robak
Antibody-drug conjugates (ADC) are monoclonal antibodies (Mabs) attached to biologically active drugs through specialized chemical linkers. They deliver and release cytotoxic agents at the tumor site, reducing the likelihood of systemic exposure and therefore toxicity. These agents should improve the potency of chemotherapy by increasing the accumulation of the cytotoxic drug within or near the neoplastic cells with reduced systemic effects. Areas covered and methods: A literature review was conducted using the MEDLINE database, PubMed, for articles in English examining Mabs, B-cell receptor pathway inhibitors and immunomodulating drugs...
August 9, 2017: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/28770352/primary-ovarian-burkitt-s-lymphoma-a-rare-oncological-problem-in-gynaecology-a-review-of-literature
#5
REVIEW
Anna Stepniak, Piotr Czuczwar, Piotr Szkodziak, Ewa Wozniakowska, Slawomir Wozniak, Tomasz Paszkowski
PURPOSE: This review presents the information about epidemiology, clinical manifestation, diagnosis and treatment of primary ovarian Burkitt's lymphoma (BL), including a literature search of available BL cases. The purpose of this review is to draw clinicians' attention to the possibility of ovarian BL occurrence, which may be important in the differential diagnosis of ovarian tumours. METHODS: PubMed and Web of Science databases were searched using the keywords ''Burkitt's'', ''Lymphoma'', ''Ovarian'', ''Primary'', ''Burkitt's lymphoma''...
August 2, 2017: Archives of Gynecology and Obstetrics
https://www.readbyqxmd.com/read/28762462/radiation-induced-neurocognitive-dysfunction-in-head-and-neck-cancer-patients
#6
Francesca De Felice, Pierre Blanchard
It might seem odd that a special issue about Gianni Bonadonna would publish a review on radiation-induced neurocognitive dysfunction. Dr. Gianni Bonadonna is considered a pioneer in medical oncology history, mainly due to new and revolutionary treatment approaches proposed in breast cancer and Hodgkin lymphoma. He had an active role in the field of medical oncology, especially through lectures and textbooks. He shared his considerable insight of understanding cancer behavior and evaluating research advances over the years to prevent tumor recurrence and preserve patients from unnecessary toxicity...
July 31, 2017: Tumori
https://www.readbyqxmd.com/read/28759828/what-s-new-on-primary-hodgkin-s-lymphoma-of-the-breast-a-case-report-and-review-of-the-literature
#7
Mario Faenza, Andrea Ronchi, Antonio Santoriello, Corrado Rubino, Gorizio Pieretti, Antonio Guastafierro, Giuseppe Andrea Ferraro, Giovanni Francesco Nicoletti
INTRODUCTION: According to literature, primary Hodgkin's lymphomas of the breast represent one of the rarer entity in the primary breast lymphoma (PBL) scenario. This is the reason why these tumors are insidious in mammary oncology. PRESENTATION OF THE CASE: We report a case of HL primitive breast in an elderly patient in whom radiology suspected an advanced breast cancer with ipsilateral axillary involvement and in which the fine-needle aspiration came back not significant...
July 21, 2017: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/28753442/the-antitumor-activity-of-imgn529-a-cd37-targeting-antibody-drug-conjugate-is-potentiated-by-rituximab-in-non-hodgkin-lymphoma-models
#8
Stuart W Hicks, Katharine C Lai, L Cristina Gavrilescu, Yong Yi, Surina Sikka, Prerak Shah, Meghan E Kelly, Jenny Lee, Leanne Lanieri, Jose F Ponte, Callum M Sloss, Angela Romanelli
Naratuximab emtansine (IMGN529) is an investigational antibody-drug conjugate consisting of a CD37-targeting antibody conjugated to the maytansine-derived microtuble disruptor, DM1. IMGN529 has shown promising preclinical and clinical activity in non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL). Due to the aggressive nature of the disease, DLBCL is often treated with combination therapies to maximize clinical outcomes; therefore, we investigated the potential of combining IMGN529 with both standard-of-care and emerging therapies against multiple oncology-relevant targets and pathways...
July 25, 2017: Neoplasia: An International Journal for Oncology Research
https://www.readbyqxmd.com/read/28752057/possible-adverse-effects-of-immunotherapy-in-non-small-cell-lung-cancer-treatment-and-follow-up-of-three-cases
#9
Paul Zarogoulidis, Panos Chinelis, Anastasia Athanasiadou, Theodora Tsiouda, Georgia Trakada, Anastasios Kallianos, Lemonia Veletza, Dimitris Hatzibougias, Electra Mihalopoulou, Eirini Goupou, Christoforos Kosmidis, Chrysanthi Sardeli, Haidong Huang, Wolfgang Hohenforst-Schmidt
In the past decade novel agents are on the market for non-small cell lung cancer adenocarcinoma based on pharmacogenomics. The epidermal growth factor receptor mutation, anaplastic lymphoma kinase and programmed death-ligand 1 investigation is necessary in the everyday clinical practice for the oncologic patient. Immunotherapy is nowadays the novel therapy for advanced stage non-small cell lung cancer with two agents nivolumab and pembrolizumab. In the current case series we will present adverse effects from our centers and comment on the treatment and follow-up of the patients...
2017: Respiratory Medicine Case Reports
https://www.readbyqxmd.com/read/28749424/drug-discovery-by-molecular-imaging-and-monitoring-therapy-response-in-lymphoma
#10
REVIEW
Senthilkumar Kalimuthu, Ju Hye Jeong, Ji Min Oh, Byeong-Cheol Ahn
Molecular imaging allows a noninvasive assessment of biochemical and biological processes in living subjects. Treatment strategies for malignant lymphoma depend on histology and tumor stage. For the last two decades, molecular imaging has been the mainstay diagnostic test for the staging of malignant lymphoma and the assessment of response to treatment. This technology enhances our understanding of disease and drug activity during preclinical and clinical drug development. Here, we review molecular imaging applications in drug development, with an emphasis on oncology...
July 27, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28747447/long-term-aids-related-pcnsl-outcomes-with-hd-mtx-and-combined-antiretroviral-therapy
#11
Antoine Moulignier, Cédric Lamirel, Hervé Picard, Marie-Gisèle Lebrette, Corinne Amiel, Mohammed Hamidi, Marc Polivka, Jacqueline Mikol, Isabelle Cochereau, Gilles Pialoux
OBJECTIVE: To assess the characteristics and outcomes of patients with AIDS-related primary CNS lymphoma (AR-PCNSL) in the combined antiretroviral therapy (cART) era systematically treated with high-dose methotrexate (HD-MTX). METHODS: We retrospectively analyzed (intention-to-treat analysis) 51 consecutive patients with AR-PCNSL (median age 39 years) who were diagnosed from 1996 to 2014 and treated with a median of 6 (range 1-15) infusions of HD-MTX (3 g/m(2)) combined with cART...
July 26, 2017: Neurology
https://www.readbyqxmd.com/read/28739458/effects-of-chemotherapy-in-patients-with-concomitant-aortic-aneurysm-and-malignant-disease
#12
Marco Leopardi, Evelina Di Marco, Aldo Musilli, Enrico Ricevuto, Gemma Bruera, Marco Ventura
BACKGROUND: The aim of the study is to present the results in a consecutive series of patients affected by aortic abdominal aneurysm and to underline the aneurysmal growth and evolution in oncological patients submitted to dedicated oncological medical therapy. METHODS: Between January 2010 and June 2016 we treated in our center 19 patients for coexisting aortic aneurysms (>3cm) and malignancy. We observed patients undergoing oncological treatment and patients who did not undergo medical treatment...
July 21, 2017: Annals of Vascular Surgery
https://www.readbyqxmd.com/read/28735365/an-update-on-the-use-of-immunotherapy-in-the-treatment-of-lymphoma
#13
REVIEW
Thomas U Marron, Matko Kalac, Joshua Brody
PURPOSE OF REVIEW: Throughout the field of oncology, immunotherapy is moving further towards the first-line setting, and there is encouraging data for the use of these novel therapies in the management of lymphomas, utilizing treatments approved for both solid and hematologic malignancies. Herein, we review promising advances in this rapidly moving field from the past year. RECENT FINDINGS: In the last year, we have seen promising clinical data on engineered antibody therapies for the treatment of lymphomas, as well as further optimization of engineered antibody fragments fused onto linkers or chimeric T cell receptors, both of the modalities capable of transforming non-specific T cells into tumor-specific, serial killer cells...
July 22, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28718335/variability-of-performance-status-assessment-between-patients-with-hematologic-malignancies-and-their-physicians
#14
Alexis D Leal, Cristine Allmer, Matthew J Maurer, Tait D Shanafelt, James R Cerhan, Brian K Link, Carrie A Thompson
This study was conducted to determine the incidence of inter-observer variability in Eastern Cooperative Oncology Group (ECOG) performance status (PS) rating between patients with leukemia and lymphoma and their physicians. ECOG PS was assessed at diagnosis by patients and their physicians and stratified by disease subtype, gender, age, disease stage and education. Association between patient- and physician-rated PS and overall survival (OS) was stratified by subtype and prognostic risk score. Overall, 65% of patients and physicians rated PS the same...
July 18, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28717759/quality-oncology-practice-initiative-can-guide-and-improve-oncology-providers-training-in-brazil
#15
Cristiane Decat Bergerot, Errol J Philip, Paulo Gustavo Bergerot, Simone Elias, Daiane Pereira Guimarães, Nora Manoukian Forones, Otavio Cesar Carvalho Guimarães Baiocchi, Nildo Alves Batista, Edvane Birelo Lopes De Domenico
PURPOSE: It has become crucial to translate scientific findings and to find ways by which to mobilize local resources to improve the quality and accessibility of cancer care in developing countries. This study seeks to provide insight into challenge through examining differences in clinician documentation of patients with cancer treated at a Brazilian Public University Hospital. METHODS: ASCO Quality Oncology Practice Initiative (QOPI) measures were used to examine the care provided in the departments of breast, colorectal, lymphoma, gynecology, and lung cancers...
June 2017: Journal of Global Oncology
https://www.readbyqxmd.com/read/28711571/effectiveness-of-single-dose-rasburicase-in-patients-with-lymphoid-malignancies-at-a-high-risk-for-tumor-lysis-syndrome
#16
Young-Woo Jeon, Dae-Hun Kwak, Sung-Soo Park, Jae-Ho Yoon, Sung-Eun Lee, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Seok Lee, Chang-Ki Min, Jong-Wook Lee, Woo-Sung Min, Seok-Goo Cho
BACKGROUND: Tumor lysis syndrome (TLS) is a life-threatening disorder that occurs mainly in patients with high-tumor burden hemato-oncologic malignancies. It results in metabolic derangements, including hyperuricemia and acute renal failure. The powerful management for TLS is a daily dose of rasburicase for up to 5 days before chemotherapy; however, the optimal dose and duration of rasburicase for TLS prophylaxis have not been standardized for patients at high risk for TLS. Therefore, we evaluated the efficacy of single-dose rasburicase for prophylactic purposes in patients with malignant lymphoma at high risk for TLS...
June 27, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/28702411/diffuse-large-b-cell-lymphoma-in-elderly-experience-from-a-tertiary-care-oncology-center-in-south-india
#17
K N Lokesh, M C Suresh Babu, K C Lakshmaiah, K Govind Babu, Smitha C Saldanha, D Loknatha, Linu Abraham Jacob, S Vishwanath, C S Premalatha, P R Kiran
INTRODUCTION: Diffuse large B-cell lymphoma (DLBCL) is the most frequent non-Hodgkins lymphoma in the elderly. With the rising proportion of older persons in India, it is important to study current patterns and management of this disease, given that data in this regard are scarce in Indian settings. The aim of this study was to document the clinical features of DLBCL among elderly patients and their outcome over 7 years at a tertiary care oncology center. MATERIALS AND METHODS: This was a retrospective records review of 119 DLBCL cases between January 2007 and January 2015 aged 60 years and above done at Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India...
April 2017: South Asian Journal of Cancer
https://www.readbyqxmd.com/read/28702410/plasmablastic-lymphoma-in-immunocompetent-and-in-immunocompromised-patients-experience-at-a-regional-cancer-centre-in-india
#18
A H Rudresha, K C Lakshmaiah, Ankit Agarwal, K Govind Babu, D Loknatha, Linu Abraham Jacob, Suresh Babu, K N Lokesh, L K Rajeev
INTRODUCTION: Plasmablastic lymphoma (PBL) is a rare lymphoma associated with immunosuppression. It is strongly associated with immunosuppression (human immunodeficiency virus [HIV]) and often occurs within the oral cavity. PBL is also seen in patients receiving immunosuppressive therapy; however, despite its predisposition for the immunocompromised patients, PBL has been diagnosed in immunocompetent patients. AIM: This study aims to prognostic factors and outcome of PBL in immunocompromised and in immunocompetent patients...
April 2017: South Asian Journal of Cancer
https://www.readbyqxmd.com/read/28701224/the-150-most-important-questions-in-cancer-research-and-clinical-oncology-series-questions-40-49
#19
EDITORIAL
(no author information available yet)
Since the beginning of 2017, Chinese Journal of Cancer has published a series of important questions in cancer research and clinical oncology, which sparkle diverse thoughts, interesting communications, and potential collaborations among researchers all over the world. In this article, 10 more questions are presented as followed. Question 40. Why do mice being used as tumorigenesis models raised in different places or different conditions possess different tumor formation rate? Question 41. How could we generate more effective anti-metastasis drugs? Question 42...
July 13, 2017: Chinese Journal of Cancer
https://www.readbyqxmd.com/read/28700812/disparities-in-location-of-death-of-adolescents-and-young-adults-with-cancer-a-longitudinal-population-study-in-california
#20
Nitya Rajeshuni, Emily E Johnston, Olga Saynina, Lee M Sanders, Lisa J Chamberlain
BACKGROUND: Patients with a terminal illness should have access to their chosen location of death. Cancer is the leading cause of non-accidental death among adolescents and young adults (AYAs; those aged 15-39 years). Although surveys have suggested that a majority of these patients prefer a home death, to the authors' knowledge, little is known regarding their barriers to accessing their preferred location of death. As a first step, the authors sought to determine, across a large population, 20-year trends in the location of death among AYA patients with cancer...
July 12, 2017: Cancer
keyword
keyword
63324
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"